Parametrica Management Ltd purchased a new position in Allergan plc (NYSE:AGN) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 2,100 shares of the company’s stock, valued at approximately $307,000.
A number of other hedge funds have also made changes to their positions in the stock. BlackRock Inc. lifted its position in Allergan by 2.9% during the fourth quarter. BlackRock Inc. now owns 21,466,017 shares of the company’s stock valued at $2,869,149,000 after buying an additional 600,535 shares during the period. Oregon Public Employees Retirement Fund lifted its position in Allergan by 14,208.8% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 20,762,744 shares of the company’s stock valued at $155,000 after buying an additional 20,617,639 shares during the period. Longview Partners Guernsey LTD lifted its position in Allergan by 288.6% during the fourth quarter. Longview Partners Guernsey LTD now owns 6,026,108 shares of the company’s stock valued at $805,450,000 after buying an additional 4,475,447 shares during the period. Janus Henderson Group PLC lifted its position in Allergan by 27.6% during the first quarter. Janus Henderson Group PLC now owns 5,855,576 shares of the company’s stock valued at $857,312,000 after buying an additional 1,265,742 shares during the period. Finally, FMR LLC lifted its position in Allergan by 6.1% during the fourth quarter. FMR LLC now owns 4,253,740 shares of the company’s stock valued at $568,554,000 after buying an additional 245,322 shares during the period. 81.74% of the stock is owned by institutional investors.
In other Allergan news, Chairman Brent L. Saunders acquired 1,760 shares of Allergan stock in a transaction that occurred on Thursday, March 7th. The stock was bought at an average cost of $143.67 per share, for a total transaction of $252,859.20. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 0.08% of the stock is currently owned by company insiders.
AGN opened at $140.34 on Friday. The company has a quick ratio of 0.60, a current ratio of 0.71 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $45.91 billion, a PE ratio of 8.41, a P/E/G ratio of 1.24 and a beta of 1.32. Allergan plc has a 1 year low of $125.84 and a 1 year high of $197.00.
Allergan (NYSE:AGN) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $3.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.55 by $0.24. The firm had revenue of $3.60 billion during the quarter, compared to analyst estimates of $3.55 billion. Allergan had a positive return on equity of 8.45% and a negative net margin of 45.94%. Allergan’s quarterly revenue was down 2.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.74 EPS. Sell-side analysts forecast that Allergan plc will post 16.68 earnings per share for the current fiscal year.
Allergan announced that its board has approved a stock repurchase program on Tuesday, January 29th that allows the company to repurchase $2.00 billion in shares. This repurchase authorization allows the company to purchase up to 4.1% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Tuesday, May 14th will be issued a $0.74 dividend. The ex-dividend date is Monday, May 13th. This represents a $2.96 annualized dividend and a yield of 2.11%. Allergan’s payout ratio is 17.74%.
TRADEMARK VIOLATION NOTICE: “Parametrica Management Ltd Takes $307,000 Position in Allergan plc (AGN)” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.tickerreport.com/banking-finance/4344511/parametrica-management-ltd-takes-307000-position-in-allergan-plc-agn.html.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.